Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Journal of Experimental & Clinical Cancer ResearchOpen Access

Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJingwen LiuJJJia JiangJHJu Huang

Discussion

Loading...

Member takes

Overview

Observational cohort study highlights bufalin's potential to improve survival in hepatocellular carcinoma patients, suggesting EGFR pathway blockade implications.

Key Points

  • Bufalin significantly reduces tumor volume in hepatocellular carcinoma models, indicating potential as a therapeutic agent.
  • Survival outcomes indicate that bufalin in combination with Cinobufacini may enhance overall survival and progression-free survival in HCC patients.
  • Mechanistic studies reveal that bufalin inhibits EGFR-mediated RAS-RAF-MEK-ERK pathway activation, crucial for HCC progression.
  • Clinical insights show a possible dose-response relationship between Cinobufacini exposure and treatment outcomes for HCC.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c23922b210217d6477a9f0https://doi.org/10.1186/s13046-025-03531-3
View Full Paper
Ask AI
Bookmark
Share